|
|
 |
|
Viewing report
|
|
|
|
Special Report: Opportunities in Emerging Markets-Developing Asia
Decision Resources, Inc, Aug 2011
Asia boasts 6 of the 20 largest economies in the world: China, Japan, India, Russia, Australia, and Indonesia. The countries of developing Asia are all categorized as emerging and developing economies. Pharmaceutical companies mostly prioritize Brazil, Russia, India, China, Mexico, and Turkey (BRIC-MT) for their emerging market strategies. Two of these markets, China and India, are in developing Asia. Other small and midsize developing Asian markets also offer significant opportunities to pharma companies looking to expand in emerging markets. In this report, Decision Resources investigate the emerging markets of developing Asia and compare them with the advanced economies of Australia, Japan, New Zealand, the United States, and the other emerging BRIC-MT economies. They explore the differences and similarities among these diverse markets and discuss strategies and opportunities for pharmaceutical companies in developing Asia.
- The International Monetary Fund forecasts significant growth in many developing Asian economies for 2011. Which of these economies will experience the fastest growth in 2011 over 2010? How does it compare with expected growth in other BRIC-MT economies and advanced economies?
- The World Economic Forum (WEF) assesses the strengths and weaknesses of countries around the world and issues an annual global competitiveness index (GCI) that ranks country economies. How do the emerging markets of developing Asia compare with those of the other BRIC-MT countries? How do they compare with the advanced economies of Australia, Japan, New Zealand, and the United States?
- The Indian Patent Act of 2005 reintroduced product patent protection for pharmaceuticals and brought India's patent laws into compliance with the World Intellectual Property Organization's (WIPO) requirements. Why is obtaining pharmaceutical patents in India still challenging? Which companies have run into difficulties, and what is the current status of these patent cases?
- Many developing Asian countries have mostly rural populations where access to healthcare and pharmaceuticals is more difficult. Which developing Asian countries have predominantly urban and which have predominantly rural populations? What opportunities exist for pharmaceutical companies in rural markets? What pharma initiatives are under way in India?
- India has been referred to as the pharmacy to the world. Why is this country well suited as a regional manufacturing hub for generics? How strong is the Indian export market?
- The Chinese government is proactively working to increase the supply of better healthcare and pharmaceuticals, causing many MNCs to increase their investment footprint in China. What initiatives is the Chinese government taking? What are MNCs, domestic pharma companies, and distributors doing to increase their competitive position in China?
- In an analysis of 15 parameters tracked by the World Economic Forum (WEF), certain developing Asian countries often ranked among the bottom five countries. Which countries ranked low on which parameters? What were the top problems for doing business in those countries? Which countries consistently ranked high on the WEF parameters?
Scope:
Geographies: Developing Asia, Afghanistan, Bangladesh, Bhutan, Brunei, Cambodia, China, India, Indonesia, Laos, Malaysia, Maldives, Myanmar, Nepal, Pakistan, Philippines, Sri Lanka, Thailand, Timor-Leste, and Vietnam; Oceania, Fiji, Kiribati, Papua New Guinea, Samoa, Solomon Islands, Tonga, Tuvalu, and Vanuatu; advanced economies of Australia, Japan, New Zealand, and the United States; emerging markets of Brazil, Russia, India, China, Mexico, Turkey (BRIC-MT).
Emerging versus advanced market comparisons: Global competitive index, population, gross domestic product (GDP), GDP per capita, health expenditures per capita, private and out-of-pocket health expenditures, physician density, pharmaceutical personnel density, infant mortality, life expectancy, correlation of worker productivity to pay, labor force female-to-male ratio, quality of math and science education, prevalence of trade barriers, number of clinical trials, intellectual property protection, foreign ownership of companies, favoritism in decisions by government officials, utility patents, intensity of local competition, extent of market dominance, financial services, local equity markets, venture capital.
Pharmaceutical industry: Recent deals, clinical trials, export markets, multinational corporations (MNCs), investments, initial public offerings, domestic companies, distributors, leading companies, contract organizations, healthcare, market size, generics, bolt-on acquisitions, patent environment, drug portfolios, innovative brands, market share, branded generics, manufacturing, investments, rural markets, consolidation, data exclusivity, free trade agreements.
Expert insight:Barrie G. James, Ph.D., provides insight on recent news and events relating to the pharmaceutical industry in China. Dr. James is the principal of Pharma Strategy Consulting in the United Kingdom. Previously, he held executive positions at Ciba-Geigy, Merck & Co., Syntex, and Schering-Plough in strategic planning, marketing, and business development.
Expert insight:Peter Wittner, principal, Interpharm Consultancy, provides insight on recent news and events relating to the healthcare and pharmaceutical industries in India. Mr. Wittner specializes in generics strategies. Previously, he worked at Ranbaxy (U.K.), H.N. Norton (subsequently part of Ivax), Evans Medical, A.H. Robins, and Koppel & Co. in general management, business development, and sales and marketing.
Exhibits: 27 data-rich tables and figures.
|
|
|
|
